Enanta Net Income Applicable To Common Shares from 2010 to 2026

ENTA Stock  USD 13.85  0.01  0.07%   
Enanta Pharmaceuticals' Net Loss is decreasing over the years with slightly volatile fluctuation. Overall, Net Loss is projected to go to about -104.1 M this year. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2010-09-30
Previous Quarter
-37.7 M
Current Value
-39.1 M
Quarterly Volatility
22.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Enanta Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enanta Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.1 M, Interest Expense of 9.3 M or Selling General Administrative of 28.5 M, as well as many indicators such as Price To Sales Ratio of 7.99, Dividend Yield of 0.0 or PTB Ratio of 2.1. Enanta financial statements analysis is a perfect complement when working with Enanta Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Enanta Stock
Check out the analysis of Enanta Pharmaceuticals Correlation against competitors.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.
Analyzing Enanta Pharmaceuticals's Net Income Applicable To Common Shares over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income Applicable To Common Shares has evolved provides context for assessing Enanta Pharmaceuticals's current valuation and future prospects.

Latest Enanta Pharmaceuticals' Net Income Applicable To Common Shares Growth Pattern

Below is the plot of the Net Income Applicable To Common Shares of Enanta Pharmaceuticals over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Enanta Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enanta Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income Applicable To Common Shares10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

Enanta Net Income Applicable To Common Shares Regression Statistics

Arithmetic Mean(29,798,766)
Coefficient Of Variation(253.33)
Mean Deviation67,938,105
Median(6,569,000)
Standard Deviation75,488,829
Sample Variance5698.6T
Range200.7M
R-Value(0.81)
Mean Square Error2086.1T
R-Squared0.66
Significance0.00008
Slope(12,115,200)
Total Sum of Squares91177T

Enanta Net Income Applicable To Common Shares History

2026-104.1 M
2025-109.6 M
2021-121.8 M
2020-79 M
2019-36.2 M
201846.4 M
201772 M

About Enanta Pharmaceuticals Financial Statements

Enanta Pharmaceuticals stakeholders use historical fundamental indicators, such as Enanta Pharmaceuticals' Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although Enanta Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Enanta Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Enanta Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Enanta Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-109.6 M-104.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:
Check out the analysis of Enanta Pharmaceuticals Correlation against competitors.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. Projected growth potential of Enanta fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Enanta Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
(0.66)
Earnings Share
(3.21)
Revenue Per Share
2.885
Quarterly Revenue Growth
0.098
Return On Assets
(0.13)
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Enanta Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Enanta Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Enanta Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.